Neil Flash joins med comms group Lucid as chief commercial officerLucid Group has appointed Neil Flash to the newly-created role of chief commercial officer. He will also serve Share XNeil Flash joins med comms group Lucid as chief commercial officerhttps://pharmaphorum.com/news/lucid-group-neil-flash/
Babylon Health to create city-wide digital health service with UK hospitalBabylon Health, the company behind the GP at Hand phone app being piloted in the NHS, has partnered Share XBabylon Health to create city-wide digital health service with UK hospitalhttps://pharmaphorum.com/news/babylon-health-to-create-city-wide-digital-health-service-with-uk-hospital/
PatchAi launches virtual assistant for clinical trial patientsThe Italian startup PatchAi has launched an empathic virtual assistant designed to help patients taking part in the Share XPatchAi launches virtual assistant for clinical trial patientshttps://pharmaphorum.com/news/patchai-launches-virtual-assistant-for-clinical-trial-patients/
Roche edges closer to SMA market as risdiplam hits target in trial in babiesRoche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the Share XRoche edges closer to SMA market as risdiplam hits target in trial in babieshttps://pharmaphorum.com/news/roche-sma-risdiplam-babies/
Bayer gets Japanese approval for prostate cancer drug NubeqaBayer and Orion’s prostate cancer drug Nubeqa (darolutamide) is gaining steam in its battle against rivals from J&J Share XBayer gets Japanese approval for prostate cancer drug Nubeqahttps://pharmaphorum.com/news/bayer-gets-japanese-approval-for-prostate-cancer-drug-nubeqa/
Race is on to find coronavirus vaccine as outbreak escalatesThe race is on to find a vaccine for the coronavirus outbreak that has put an entire Chinese Share XRace is on to find coronavirus vaccine as outbreak escalateshttps://pharmaphorum.com/news/race-is-on-to-find-coronavirus-vaccine-as-outbreak-escalates/
Poor data hindering machine learning in drug R&DA lack of high-quality data is hindering use of machine learning in drug development, according to a new Share XPoor data hindering machine learning in drug R&Dhttps://pharmaphorum.com/news/poor-data-hindering-machine-learning-in-drug-rd/
NHS patients denied new lung cancer drug after another NICE deadlockCertain untreated lung cancer patients on England’s NHS will have to make do with older drugs after NICE Share XNHS patients denied new lung cancer drug after another NICE deadlockhttps://pharmaphorum.com/news/nice-deadlock/
Call for mandatory disclosure of industry funding of patient groupsExperts have warned that few patient groups have formal policies governing corporate funding and financial transparency, despite widespread Share XCall for mandatory disclosure of industry funding of patient groupshttps://pharmaphorum.com/news/call-for-mandatory-disclosure-of-industry-funding-of-patient-groups/
AstraZeneca commits to being carbon negative by 2030AstraZeneca has announced its ambition to have zero carbon emissions from its global operations by 2025 and to Share XAstraZeneca commits to being carbon negative by 2030https://pharmaphorum.com/news/astrazeneca-commits-to-being-carbon-negative-by-2030/
UK biotech PhoreMost to work with Otsuka on gene therapy projectsBuilding on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun Share XUK biotech PhoreMost to work with Otsuka on gene therapy projectshttps://pharmaphorum.com/news/uk-biotech-phoremost-to-work-with-otsuka-on-gene-therapy-projects/
Janssen’s Darzalex approved in EU for newly-diagnosed multiple myelomaJanssen’s Darzalex (daratumumab) has been approved in Europe as a combination therapy in newly-diagnosed patients with multiple myeloma. Share XJanssen’s Darzalex approved in EU for newly-diagnosed multiple myelomahttps://pharmaphorum.com/news/janssens-darzalex-approved-in-eu-for-multiple-myeloma/
AI-powered study backs anticoagulants for heart failure patients without AFA new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of Share XAI-powered study backs anticoagulants for heart failure patients without AFhttps://pharmaphorum.com/news/ai-powered-study-backs-anticoagulants-for-heart-failure-patients-without-af/
Novartis’ Mayzent EU approval offers SPMS patients new optionNovartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share XNovartis’ Mayzent EU approval offers SPMS patients new optionhttps://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
Durect’s post-op painkiller splits FDA advisory panelAs the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new Share XDurect’s post-op painkiller splits FDA advisory panelhttps://pharmaphorum.com/news/durects-post-op-painkiller-splits-fda-advisory-panel/
WHO criticises lack of big pharma antibiotic R&DBig pharma still continues to look upon antibiotic resistance as somebody else’s problem, the World Health Organization has Share XWHO criticises lack of big pharma antibiotic R&Dhttps://pharmaphorum.com/news/who-bemoans-lack-of-big-pharma-antibiotic-rd/
Synaptive Medical adds 3D visualisation and voice activation to its surgical techRobotic surgical visualisation company Synaptive Medical has updated its Modus V – a fully automated robotic digital microscope Share XSynaptive Medical adds 3D visualisation and voice activation to its surgical techhttps://pharmaphorum.com/digital/synaptive-medical-adds-3d-visualisation-and-voice-activation-to-its-surgical-tech/
AZ and MSD’s Lynparza gets fast prostate cancer FDA reviewThe FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the Share XAZ and MSD’s Lynparza gets fast prostate cancer FDA reviewhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/
Hearing Medicines Discovery Syndicate launches to fast-track the development of hearing therapeutics Share XHearing Medicines Discovery Syndicate launches to fast-track the development of hearing therapeuticshttps://pharmaphorum.com/partner-content/hearing-medicines-discovery-syndicate-launches-to-fast-track-the-development-of-hearing-therapeutics/
Speaker interview MRC Harwell Institute ahead of SMi’s 3D Cell Culture Share XSpeaker interview MRC Harwell Institute ahead of SMi’s 3D Cell Culturehttps://pharmaphorum.com/partner-content/speaker-interview-mrc-harwell-institute-ahead-of-smis-3d-cell-culture/
Pre-Filled Syringes East Coast to discuss Digital Connectivity in the PFS Industry Share XPre-Filled Syringes East Coast to discuss Digital Connectivity in the PFS Industryhttps://pharmaphorum.com/partner-content/pre-filled-syringes-east-coast-to-discuss-digital-connectivity-in-the-pfs-industry/
Maximising the reach of your publications Share XMaximising the reach of your publicationshttps://pharmaphorum.com/partner-content/maximising-the-reach-of-your-publications/
Envision Pharma Group appoints David Thompson as CEO Share XEnvision Pharma Group appoints David Thompson as CEOhttps://pharmaphorum.com/news/envision-pharma-group-ceo-david-thompson/
Kristin Milburn joins Healthware Group as Global Head of Digital Health Partnerships Share XKristin Milburn joins Healthware Group as Global Head of Digital Health Partnershipshttps://pharmaphorum.com/partner-content/kristin-milburn-joins-healthware-group-as-global-head-of-digital-health-partnerships/
